Deep Remission With Vedolizumab in Patients With Moderately to Severely Active Ulcerative Colitis: A GEMINI 1 post hoc Analysis

BACKGROUND AND AIMS: This GEMINI 1 post hoc analysis evaluated vedolizumab efficacy for inducing deep remission in patients with ulcerative colitis and correlation between vedolizumab trough concentrations and deep remission rates. METHODS: Week 6 vedolizumab responders were re-randomized to placebo...

Descripción completa

Detalles Bibliográficos
Autores principales: Sandborn, William J, Colombel, Jean-Frédéric, Panaccione, Remo, Dulai, Parambir S, Rosario, Maria, Cao, Charlie, Barocas, Morris, Lasch, Karen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6357899/
https://www.ncbi.nlm.nih.gov/pubmed/30285104
http://dx.doi.org/10.1093/ecco-jcc/jjy149

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6357899/
https://www.ncbi.nlm.nih.gov/pubmed/30285104
http://dx.doi.org/10.1093/ecco-jcc/jjy149

Ejemplares similares